FDA approves first nasal spray for severe allergic reactions. Here's what to know.

The Food and Drug Administration approved a nasal spray intended to treat severe allergic reactions on Friday, expanding options beyond needle-based treatments like the EpiPen.

The nasal spray, called Neffy, from drugmaker ARS Pharmaceuticals, is approved for the treatment of allergic reactions, including life-threatening anaphylaxis, in adults and children who weigh at least 66 pounds.

The approval comes nearly a year after the FDA previously decided not to approve Neffy, pending more trial data. According to ARS, the FDA regulators decided at the time that more data was needed to evaluate the safety of repeated doses of the nasal spray before it could be approved.